CELZ-201-DDT not checked
Creative Medical Technology Holdings Inc
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.”In the company’s words, NCT06053242 on ClinicalTrials.gov
- Tested for
- Chronic Low-back Pain, Degenerative Disc Disease
- Main trialPhase 1/2
- “The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.”In the company’s words, NCT06053242 on ClinicalTrials.gov
Other drugs for Chronic Low-back Pain
- IDCTDiscGenics, Inc. · Phase 3
- LY4065967Eli Lilly · Phase 2
- CNTX-3001Centrexion Therapeutics · Phase 1
- Lumbar InjectionsR3 Stem Cell · Phase 1
Coming up1
- 20 Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 20 Jan 2027 | Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026